Previous 10 | Next 10 |
Guardant’s Impact, Innovation, Ambition, and Success Contributed to the Recognition Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its inclusion in the fourth-annual TIME100 Most Influential Companies list, highlighting companies making...
Studies demonstrate benefits of liquid biopsy and real-world data in targeted therapy selection and therapeutic outcomes in advanced breast cancer Interim data from PICI’s RADIOHEAD study using Guardant Infinity™ platform show correlation between epigenomic biomarkers and pa...
2024-05-27 11:34:31 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the S&P 500 sitting just a few points below setting a new all-time high, the bull market that began in 2022 is still snorting. Although a correction or even a bear market will even...
2024-05-24 21:15:02 ET Stephens analyst issues BUY recommendation for GH on May 24, 2024 05:00PM ET. The previous analyst recommendation was Buy. GH was trading at $25.52 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...
2024-05-24 21:15:01 ET Piper Sandler analyst issues UNDERPERFORM recommendation for GH on May 24, 2024 05:00PM ET. The previous analyst recommendation was Underperform. GH was trading at $25.52 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-24 09:25:08 ET More on Guardant Health Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript Guardant Health: Shield Launch Could Drive Multiple Expansion Guardant Health colorectal cancer screening test endorsed by FDA advisors Guardant shares ...
The advisory committee offers valuable non-binding recommendations for the FDA Blood test offers a convenient non-invasive screening option that overcomes barriers associated with current non-invasive screening tests Shield remains on track to become the first FDA-approved blood t...
2024-05-23 17:05:39 ET More on Guardant Health Guardant Health slips as FDA comments on cancer screening test Guardant Health: Shield Launch Could Drive Multiple Expansion Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quan...
2024-05-23 08:39:07 ET More on Guardant Health Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript Guardant Health: Shield Launch Could Drive Multiple Expansion Guardant Health slips as FDA comments on cancer screening test Guardant Health Non-GAAP EP...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock. The Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee will meet to...
News, Short Squeeze, Breakout and More Instantly...